Therefore, specific LXRβ activation could potentially dissociate the LXR agonists' anti-atherosclerotic and anti-diabetic effects from their hypertriglyceridaemic effects and possibly serve as the basis of a treatment for T2DM [10,15]. This evidence concerns the gene NR1H2 and type 2 diabetes mellitus.